Summary of Clinical Use

Phase 2 clinical trial (NCT01999192) in patients with active RA and an inadequate response to methotrexate, was terminated early as the therapy failed to show clinical efficacy above methotrexate control [3].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01999192	Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis	Phase 2 Interventional	Biotest